San Francisco – October 27, 2025
Groundbreaking clinical experience with multi-organ denervation (targeting both hepatic and renal arteries) was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2025.
The presentation highlighted the latest clinical outcomes from multi-organ denervation studies using next-generation denervation systems to treat patients with type 2 diabetes and hypertension — two of the most prevalent and difficult-to-control chronic diseases.
All procedures were performed in Tbilisi, Georgia, by the CardioVascular Global team led by Prof. Dr. Horst Sievert and Dr. Kolja Sievert, in collaboration with the Israeli-Georgian Medical Research Center Helsicore (Dr. Irakli Gogorishvili), Tbilisi Heart and Vascular Clinic (Dr. Giorgi Khabeishvili), and Tbilisi Heart Centre (Dr. Archil Chukhrukidze).
The procedures demonstrated excellent safety and meaningful reductions in HbA1c and 24-hour systolic blood pressure during follow-up. CardioVascular Global continues to cooperate with international partners to advance this therapy through new studies and structured training programs, and has been invited to support Neurotronic’s forthcoming U.S. clinical trial as international proctors.